The loss of DUSP1 expression is a characteristic of TSCs and is associated with the expression of tumor stem cell markers (ABCG2, NANOG, SOX2, PROM1, and L1CAM) in situ, which indicates that DUSP1 participates in the survival of these therapeutically resistant patients associated with GBM.110. The gene discussed is DUSP1; the disease is glioblastoma.